DiviTum® TKa assay Clinical Trials
2 recruitingDevice
Not Applicable2
Showing 1–2 of 2 trials
Recruiting
Not Applicable
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
Breast CancerCancer of the Breast
Washington University School of Medicine55 enrolled1 locationNCT04968964
Recruiting
Not Applicable
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
Metastatic Breast CancerUnresectable Breast Cancer
Washington University School of Medicine65 enrolled1 locationNCT05977036